Trials / Not Yet Recruiting
Not Yet RecruitingNCT05750589
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- iRenix Medical, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IRX-101 | IRX-101 is a novel ocular anti-septic |
| DRUG | Providone-Iodine | 5% Providone-Iodine |
Timeline
- Start date
- 2026-09-01
- Primary completion
- 2027-01-31
- Completion
- 2027-12-31
- First posted
- 2023-03-01
- Last updated
- 2026-04-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05750589. Inclusion in this directory is not an endorsement.